Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | ESR1 | P03372 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830366 | 0.95 | KMT2A (0.82) | KMT2AMEN1LMNAMAPTNPC1 | |
| SCHEMBL13932521 | 0.90 | KMT2A (0.71) | KMT2AMEN1LMNAMAPTNPC1 | |
| SCHEMBL6653763 | 0.90 | KMT2A (0.71) | KMT2AMEN1LMNAMAPTNPC1 | |
| SCHEMBL5433051 | 0.89 | MAPT (0.65) | KMT2AMEN1LMNAMAPTNPC1 | |
| SCHEMBL5057224 | 0.86 | KMT2A (0.54) | KMT2AMEN1LMNAMAPTNPC1 | |
| SCHEMBL6393345 | 0.86 | NPC1 (0.68) | KMT2AMEN1LMNAMAPTNPC1 | |
| SCHEMBL29245494 | 0.86 | KMT2A (1.00) | KMT2AMEN1LMNAMAPTNPC1 | |
| SCHEMBL1549061 | 0.86 | KMT2A (1.00) | KMT2AMEN1LMNAMAPTNPC1 | |
| SCHEMBL6399902 | 0.84 | MEN1 (0.70) | KMT2AMEN1LMNAMAPTNPC1 | |
| Hydrogen Sulfide SCHEMBL31314884 | 0.84 | KMT2A (0.96) | KMT2AMEN1LMNAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831190-B1 | Acts effectively in stomach, the antibacterial activity becomes weak as the compounds moves from duodenum to small intestines; do not have activity against esylhiacori, staphylococcus aureus, methacycline resistant bacterium | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2004-12-14 | — | — | US | claimed |
| EP-0989112-B1 | Intermediates for the preparation of guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORP (JP) | 2004-04-14 | — | — | EP | claimed |
| EP-1430025-B1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING BACTERIAL INFECTION | ZHU DEXU (CN) | 2009-01-14 | — | — | EP | disclosed |
| EP-0870500-B1 | ANTI-HELICOBACTER PYLORI AGENT | NAGASE CHEMTEX CORP (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-6960681-B2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORPORATION (JP) | 2005-11-01 | — | — | US | disclosed |
| EP-1430025-A4 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING BACTERIAL INFECTION | ZHU DEXU (CN) | 2005-04-27 | — | — | EP | disclosed |
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. | 2005-04-07 | — | — | US | disclosed |
| US-6831190-B1 | Acts effectively in stomach, the antibacterial activity becomes weak as the compounds moves from duodenum to small intestines; do not have activity against esylhiacori, staphylococcus aureus, methacycline resistant bacterium | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| EP-1449828-A2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | Nagase ChemteX Corporation (JP) | 2004-08-25 | — | — | EP | disclosed |
| EP-1430025-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING BACTERIAL INFECTION | Zhu, Dexu (CN) | 2004-06-23 | — | — | EP | disclosed |
| US-6734212-B2 | ADMINISTERING AGENT THAT SELECTIVELY INHIBITS BACTERIAL DNA REPLICATION INITIATION; FOR DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH E. COLI OR H. PYLORI INFECTION | SHANGHAI EAST BEST BIOPHARMACEUTICAL (CN) | 2004-05-11 | — | — | US | disclosed |
| WO-2003029201-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING BACTERIAL INFECTION | ZHU DEXU (CN) | 2003-04-10 | — | — | WO | disclosed |
| US-20020123508-A1 | 4-(4-(4-methylbenzyloxycarbonyl) phanyl)phenyl trans-4-guanidinomethylcyclohexanecarboxylate or acid addition salt thereof and cyclodextrin; use treating ulcers for example | NAGASE CHEMTEX CORPORATION (JP) | 2002-09-05 | — | — | US | disclosed |
| US-6444703-B1 | 4-(4-(4-METHYLBENZYLOXYCARBONYL) PHANYL)PHENYL TRANS-4-GUANIDINOMETHYLCYCLOHEXANECARBOXYLATE OR ACID ADDITION SALT THEREOF AND CYCLODEXTRIN; USE TREATING ULCERS FOR EXAMPLE | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2002-09-03 | — | — | US | disclosed |
| US-6284791-B1 | USEFUL AS AN ANTI-MICROBIAL AGAINST HELICOBACTER PYLORI | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2001-09-04 | — | — | US | disclosed |
| EP-0775692-B1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEM IND CO LTD (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0989112-A2 | Intermediates for the preparation of guanidinomethyl cyclohexane carboxylic acid ester derivatives | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
| CN-1205632-A | Anti-helicobacter pylori agent | TEIKOKU CHEMICAL IND CO LTD (JP) | 1999-01-20 | — | — | CN | disclosed |
| EP-0870500-A1 | ANTI-HELICOBACTER PYLORI AGENT | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| EP-0775692-A1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | GCK, ADCY9, ADCY7 | KMT2A 2789/4885MEN1 4345/4885LMNA 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.